Neurofibromin 2 (NF2) mutations were observed in male patients, and exploratory subgroup differences emerged across racial groups. Overall, AE appears to be driven by recurrent alterations in chromatin remodeling, p53, DNA damage response, and NOTCH signaling pathways, highlighting these areas as priorities for future biological validation and therapeutic investigation.

1 day ago

Journal

TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • KMT2D (Lysine Methyltransferase 2D) • KMT2C (Lysine Methyltransferase 2C) • NF2 (Neurofibromin 2) • NOTCH2 (Notch 2) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • EP300 (E1A binding protein p300)

TP53 mutation

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 (clinicaltrials.gov)

P2, N=104, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

2 days ago

Enrollment open

SP1-IKBIP axis promotes the proliferation and invasion of glioma with Wnt/β-catenin associated epithelial-mesenchymal transition. (PubMed, Am J Cancer Res)

These findings collectively suggest that upregulation of IKBIP promotes the proliferation and invasive behaviors of glioma cells by activating the Wnt/β-catenin/EMT pathway. Overall, our findings suggest that SP1-IKBIP axis facilitates the proliferation and invasion of glioma through Wnt/β-catenin-associated EMT, and SP1-IKBIP axis may represent a promising target for the clinical diagnosis and treatment of glioma.

3 days ago

Journal

CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • IKBIP (IKBKB Interacting Protein)

Accumulation of Siglec10+CX3CR1+ Macrophages in the Tumor Microenvironment of Glioblastomas. (PubMed, Eur J Immunol)

Moreover, the GBM tumor microenvironment (TME) is enriched in arachidonic acid (AA)-derived cyclooxygenase (COX) products prostaglandins (PG) E2 and F2α in combination with enhanced CD24 expression. By our comparative approach, the data hint toward a pro-tumorigenic Siglec10+CX3CR1+ macrophage population depending on the characteristic tumor microenvironment (TME) of highly malignant GBMs.

3 days ago

Journal

CD24 (CD24 Molecule) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • SIGLEC10 (Sialic Acid Binding Ig Like Lectin 10)

High ALG1 Expression Is Correlated With Poor Prognosis and the Immune Microenvironment in Glioma. (PubMed, J Cell Mol Med)

Knocking down ALG1 significantly reduced glioma cell migration and downregulated EMT-related proteins like N-cadherin, β-catenin, and Vimentin. This study highlights ALG1 as a key prognostic biomarker and therapeutic target for glioma, promoting malignancy through increased cell migration, EMT modulation, and an altered immunosuppressive microenvironment.

3 days ago

Journal

CTNNB1 (Catenin (cadherin-associated protein), beta 1) • IL10 (Interleukin 10) • VIM (Vimentin) • CDH2 (Cadherin 2)

A Study of Mirdametinib in People With Central Nervous System Tumors (clinicaltrials.gov)

P1/2, N=26, Recruiting, Memorial Sloan Kettering Cancer Center

3 days ago

New P1/2 trial

NF1 (Neurofibromin 1)

MSK-IMPACT

Gomekli (mirdametinib)

EBV Triggers a Distinct Antiviral Response in HMC3 Cells. (PubMed, bioRxiv)

This study demonstrates evidence for EBV particle exposure to influence microglial immune phenotypes by suppressing IFN production, providing a putative mechanism for EBV virion expression in the CNS to suppress anti-tumoral immunity against EBV+ cancers. These results are particularly relevant to the etiology of EBV+ primary CNS cancers in immunocompromised people, where microglial play a heightened role in protecting the CNS in the absence of adaptive immunity.

6 days ago

Journal

EGR1 (Early Growth Response 1)

Viral Microglia Reprogramming Clears Oligomeric Neurotoxic Debris. (PubMed, bioRxiv)

Targeting of microglia with PVSRIPO mediated immunotherapy in a mouse glioma model and the clearance of oligomeric amyloid-beta deposits in an injectable model of neurotoxic amyloid accumulation. This work identifies attenuated virotherapy as an approach to safely and effectively invigorate microglia function in immune surveillance and neurotoxic debris clearance.

6 days ago

Journal

IRF7 (Interferon Regulatory Factor 7)

NYMC195: Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies (clinicaltrials.gov)

P1, N=30, Recruiting, New York Medical College | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2026

8 days ago

Trial completion date • Trial primary completion date

temozolomide • irinotecan • vincristine • Zolinza (vorinostat)

BrainChild-03: Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (clinicaltrials.gov)

P1, N=90, Recruiting, Seattle Children's Hospital | Trial completion date: May 2041 --> May 2042 | Trial primary completion date: May 2026 --> May 2027

9 days ago

Trial completion date • Trial primary completion date

SCRI-CARB7H3(s)